- Home
- NXGL vs MIRA Comparison
NXGL vs MIRA Comparison
Compare NXGL & MIRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NXGL
- MIRA
- Stock Information
- Founded
- NXGL 1997
- MIRA 2020
- Country
- NXGL United States
- MIRA United States
- Employees
- NXGL N/A
- MIRA N/A
- Industry
- NXGL Medical/Dental Instruments
- MIRA Biotechnology: Pharmaceutical Preparations
- Sector
- NXGL Health Care
- MIRA Health Care
- Exchange
- NXGL Nasdaq
- MIRA Nasdaq
- Market Cap
- NXGL 19.7M
- MIRA 19.5M
- IPO Year
- NXGL 2021
- MIRA 2023
- Fundamental
- Price
- NXGL $2.43
- MIRA $1.50
- Analyst Decision
- NXGL
- MIRA Strong Buy
- Analyst Count
- NXGL 0
- MIRA 1
- Target Price
- NXGL N/A
- MIRA $17.00
- AVG Volume (30 Days)
- NXGL 65.0K
- MIRA 457.6K
- Earning Date
- NXGL 08-12-2025
- MIRA 08-14-2025
- Dividend Yield
- NXGL N/A
- MIRA N/A
- EPS Growth
- NXGL N/A
- MIRA N/A
- EPS
- NXGL N/A
- MIRA N/A
- Revenue
- NXGL $11,672,000.00
- MIRA N/A
- Revenue This Year
- NXGL $52.35
- MIRA N/A
- Revenue Next Year
- NXGL $42.38
- MIRA N/A
- P/E Ratio
- NXGL N/A
- MIRA N/A
- Revenue Growth
- NXGL 133.02
- MIRA N/A
- 52 Week Low
- NXGL $2.10
- MIRA $0.73
- 52 Week High
- NXGL $5.10
- MIRA $2.70
- Technical
- Relative Strength Index (RSI)
- NXGL 47.81
- MIRA 49.78
- Support Level
- NXGL $2.21
- MIRA $1.38
- Resistance Level
- NXGL $2.71
- MIRA $1.77
- Average True Range (ATR)
- NXGL 0.20
- MIRA 0.09
- MACD
- NXGL -0.02
- MIRA -0.02
- Stochastic Oscillator
- NXGL 47.06
- MIRA 35.71
About NXGL NexGel Inc
NexGel Inc manufactures high water content, electron beam cross-linked, aqueous polymer hydrogels, or gels, used for wound care, medical diagnostics, transdermal drug delivery, and cosmetics. The company specializes in custom gels by capitalizing on proprietary manufacturing technologies. The gels and consumer products are manufactured using proprietary and non-proprietary mixing, coating and cross-linking technologies.
About MIRA MIRA Pharmaceuticals Inc.
Mira Pharmaceuticals Inc is a pre-clinical-stage pharmaceutical development company with two neuroscience programs targeting a broad range of neurologic and neuropsychiatric disorders. The company's novel oral pharmaceutical marijuana, MIRA-55, is under investigation for treating adult patients suffering from anxiety and cognitive decline, often associated with early-stage dementia.